Research Reports

Key takeaways

Operating income was -$1.7M, reflecting continued pre-revenue investment in clinical development.

Net income improved 21.8% to -$1.7M from -$2.1M YoY as losses narrowed.

Diluted EPS was $-0.62, worsening -463.6% YoY due to greater per-share loss impact.

Net cash provided by operating activities was -$1.4M, better than -$2.1M YoY from controlled spending.

Full analysis

Acurx Pharmaceuticals reported a narrower net loss of -$1.7 million for Q1 2026 versus -$2.1 million in the prior year, alongside improved operating cash use of -$1.4 million compared to -$2.1 million YoY. These results stem from disciplined cost management in a pre-revenue clinical-stage company focused on advancing ibezapolstat for Clostridioides difficile infection (CDI). The 21.8% year-over-year loss improvement highlights effective expense control, even as diluted EPS deteriorated to -$0.62 from -$0.11, reflecting a higher per-share impact from the absolute loss level.

ACXP · Acurx Pharmaceuticals, Inc.

Summary

Key takeaways

Full analysis